Bio-Rad Laboratories, Inc.
BIO
$305.56
-$0.99-0.32%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -207.58% | 396.56% | 108.94% | -209.58% | 130.16% |
| Total Depreciation and Amortization | 8.87% | 6.56% | -2.81% | 0.77% | 6.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 263.32% | -1,918.99% | -101.55% | 235.72% | -125.78% |
| Change in Net Operating Assets | -232.81% | 76.83% | 120.19% | -197.87% | 132.48% |
| Cash from Operations | 3.78% | -10.32% | 4.59% | -24.08% | 67.62% |
| Capital Expenditure | 30.63% | -32.85% | 19.84% | -6.75% | 4.96% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -100.00% |
| Cash Acquisitions | 99.17% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -106.47% | 293.83% | 200.35% | 180.12% | -237.17% |
| Cash from Investing | 62.74% | -4,079.31% | 109.49% | 45.16% | -80.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -100.00% | -143.90% | 59.00% | 0.00% |
| Issuance of Common Stock | -19.05% | -2.33% | 9.97% | -23.33% | 8.51% |
| Repurchase of Common Stock | 60.16% | -37.68% | -75,944.78% | 99.87% | 0.20% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 61.48% | -39.51% | -272.22% | 72.66% | 0.62% |
| Foreign Exchange rate Adjustments | 106.79% | -800.00% | -117.61% | 238.12% | -294.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 117.50% | -554.65% | -57.08% | 1,624.02% | 117.24% |